Plasvacc Chile

Plasvacc Chile is a specialized biotechnology company focused on the production of high-quality veterinary biologics, specifically hyperimmunized plasma. As the South American subsidiary of the Australian-based Plasvacc, the company serves the equine and canine industries by providing treatments for life-threatening conditions such as Failure of Passive Transfer (FPT) and various infectious diseases. Their production process involves the hyperimmunization of donor animals to generate plasma rich in specific antibodies, which is then processed and distributed to veterinary clinics. Key products include Equiplas for horses and Caniplas for dogs, both of which are recognized for their role in providing immediate passive immunity. Plasvacc Chile maintains rigorous quality control and manufacturing standards to ensure the safety and efficacy of its biological products across the region.